Cross-Sector entity
Of the tracked stories, 5 of 8 also mention CDC, the most common co-covered peer. That works out to roughly 7 stories per week across an 8-day span. The busiest single day carried 3. regulation accounts for 3 of the 8 tracked stories, while 5 other categories carry the remainder.
8 verified stories tracked
Last mentioned: 6d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 5 of 8 also mention CDC, the most common co-covered peer. That works out to roughly 7 stories per week across an 8-day span. The busiest single day carried 3. regulation accounts for 3 of the 8 tracked stories, while 5 other categories carry the remainder. 50% of these stories carry negative sentiment. The tracked stories average 2 original sources each. This profile follows 8 Cross-Sector stories mentioning FDA across the period from September 7, 2026 to September 14, 2026.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FDA. Shared-story counts are live from our verified record — not editorial picks.
$385 million settlement announced
Abbott agrees to pay $385 million to resolve Justice Department claims and lawsuits by relators and state Attorneys General; Abbott says the deal is not a finding of fault or liability.
Updated vaccines available
Updated COVID-19 and flu vaccines become available in the Bay Area.
Coverage Highlights Market Divergence
Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
Cramer Calls NUVB 'Pure Speculation'
On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
FDA Grants Fast Track Designation to Safusidenib
Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.
Bay Area positivity hits 9%
State data show positive COVID-19 tests at moderate levels, slightly more than 9%.
Nationwide Cyclospora outbreak tied to contaminated lettuce
An ongoing nationwide Cyclospora outbreak is linked to contaminated lettuce and a Mexican farm, drawing attention to the declining FDA foreign inspection capacity.
Major SARS-CoV-2 variation emerges
A major viral variation emerges and is later named XFG or Stratus.
Trump administration relaxes COVID-19 vaccine recommendations
Federal recommendations are relaxed, creating widespread confusion in the Bay Area.
Sturgis plant reopens
Abbott reopens the largest U.S. baby formula plant by June 2022 after the shutdown.
Sturgis plant closure and recall
Abbott closes the Sturgis, Michigan facility after the FDA begins an investigation; recall covers powdered infant formula brands including Similac.
Federal emergency response
The Biden administration eases import rules, airlifts formula from Europe, and invokes federal emergency rules to prioritize U.S. production during the formula shortage.
Pandemic-driven inspector attrition begins
The COVID-19 pandemic kicks off a wave of retirements and departures among FDA inspectors that continues to this day.
Pre-pandemic baseline for FDA foreign inspections
FDA foreign food site inspections are recorded at a baseline level before the COVID-19 pandemic; subsequent records reviewed by AP show inspections have fallen nearly 35% since this year.
Abbott will pay $385M to resolve DOJ, relator, and state AG claims tied to the Sturgis formula shutdown while denying liability. The case shows how a single plant failure can create multi-front federal, qui tam, and state exposure.
Source: MedPage Today · STAT News
Updated COVID-19 and flu vaccines are now available across the Bay Area just as positive tests exceed 9%. Healthcare leaders need clear eligibility guidance and operational readiness for the 2026-27 respiratory season.
The FDA has cleared updated COVID-19 vaccines from Pfizer, Moderna, and Novavax for 2026-27, targeting the XFG/Stratus strain. The decision resets the competitive landscape for seasonal vaccine makers.
Source: eastbaytimes.com · marinij.com
A nationwide Cyclospora outbreak tied to contaminated lettuce highlights a 35% drop in FDA foreign food inspections since 2019, raising concerns about foodborne illness surveillance and prevention.
With FDA foreign food inspections down nearly 35% since 2019, contaminated lettuce linked to a Mexican farm triggered a nationwide Cyclospora outbreak—forcing importers and retailers to reassess supplier audits and traceability.
AP investigation finds FDA foreign food inspections dropped nearly 35% since 2019 as a Cyclospora outbreak tied to Mexican lettuce raises food safety compliance obligations. Counsel should anticipate increased enforcement, recalls, and civil liability across import supply chains.
Source: wvax.com · 1069thefox.com
Jim Cramer's September 3 'pure speculation' call on Nuvation Bio hits at a moment of momentum: shares rose on FDA Fast Track news and strong early IBTROZI adoption. Yet analysts forecast a full-year 2026 net loss, making the rally a contest between pipeline optionality and burn rate.
Nuvation Bio's experimental brain cancer drug safusidenib won FDA Fast Track in August 2026, but Jim Cramer on CNBC called the surging stock pure speculation. While IBTROZI showed commercial traction as the most-prescribed new lung cancer treatment in early 2026, most value still hinges on late-stage pipeline data.
Source: aol.com · finance.yahoo.com
